Shenzhen Shijin Biological Technology

Shenzhen Shijin Biological Technology is a clinical-stage biotechnology company headquartered in Shenzhen, China, dedicated to the development of next-generation immune cell therapies. The company specializes in chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR-T) technologies, with a primary focus on treating refractory and relapsed hematological malignancies. Its lead candidate, SJ007, is an innovative CAR-T therapy targeting CD7 that has demonstrated significant efficacy in clinical trials for T-cell acute lymphoblastic leukemia. Shijin Biotech leverages proprietary gene-editing techniques to overcome the technical challenges of T-cell fratricide, positioning itself as a leader in the niche of T-cell-derived cancer treatments.